Home > Result Summaries: Compounds > epoprostenol Result Summaries: epoprostenol GSKStudy ID Phase Title Summary (Download) 112300 phase 4 Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg (0 citation(s)) 115332 phase 4 A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects with Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a registered trademark of the GlaxoSmithKline group of companies.) (0 citation(s)) 116859 phase 4 Flolan® Article 81, a retrospective observational study of the cohort of pulmonary arterial hypertension patients treated by Expert Centres in Belgium with Flolan® (epoprostenol).Flolan® is a registered trademark of the GlaxoSmithKline group of companies. (0 citation(s))
